Most flexible set of dosing regimens across certain upper GI cancers, providing convenient treatment planning1-3
Consider the dosing regimen that is right for you and your patients
Additional infusion considerations:
- TEVIMBRA is administered as an IV infusion, prior to platinum-based chemotherapy for 1L patients. For patients with 2L ESCC, administer TEVIMBRA as a monotherapy
- For 150-mg and 200-mg doses: If the first 60-minute infusion is tolerated, subsequent doses may be administered over 30 minutes
- For 300-mg doses: If the first 90-minute infusion is tolerated, administer the second infusion over 60 minutes. If the second infusion is tolerated, subsequent doses may be
administered over 30 minutes - For 400-mg doses: If the first 120-minute infusion is tolerated, administer the second infusion over 60 minutes. If the second infusion is tolerated, subsequent doses may be administered over 30 minutes
The overall management of certain AEs may require treatment interruption or treatment discontinuation, depending on severity
.
Dosing Flexibility with TEVIMBRA
Dr. Dani Castillo, MD, reviews dosing with TEVIMBRA, including its flexible regimen options across upper GI cancers.
Important reminders
- TEVIMBRA should be inspected visually for particulate matter and discoloration prior to administration
- Do not coadminister other drugs through the same infusion line
- Do not administer TEVIMBRA as an intravenous push or single bolus injection
- The intravenous line must be flushed at the end of the infusion
- TEVIMBRA is for single use only. Discard any unused portion left in the vial
Frequently Asked Questions
Expand All
What are the dosing regimens available with TEVIMBRA?
TEVIMBRA offers the most flexible set of dosing regimens across indications, providing convenient treatment planning. You can synchronize TEVIMBRA with your preferred chemotherapy following a Q2W or Q3W schedule and offer convenience with fewer infusion visits for patients following a Q4W or Q6W schedule.1-3
How is TEVIMBRA administered?
TEVIMBRA is administered as an IV infusion, prior to platinum-based chemotherapy for 1L patients. For patients with 2L ESCC, TEVIMBRA is administered as a monotherapy.1
What is the infusion time for TEVIMBRA?
TEVIMBRA offers a flexible set of dosing regimens across indications with options for Q2W, Q3W, Q4W, or Q6W schedules. For 150-mg and 200-mg doses, if the first 60-minute infusion is tolerated, subsequent doses may be administered over 30 minutes. For 300-mg doses, if the first 90-minute infusion is tolerated, the second infusion may be administered over 60 minutes. If the second infusion is tolerated, subsequent doses may be administered over 30 minutes. For 400-mg doses, if the first 120-minute infusion is tolerated, the second infusion may be administered over 60 minutes. If the second infusion is tolerated, subsequent doses may be administered over 30 minutes.1
2L, second line; AE, adverse event; ESCC, esophageal squamous cell cancer; GI, gastrointestinal; IV, intravenous; Q2W, every 2 weeks; Q3W, every 3 weeks; Q4W, every 4 weeks; Q6W, every 6 weeks.
Reference: 1. TEVIMBRA. Prescribing Information. BeOne Medicines USA, Inc.; 2025. 2. Keytruda. Prescribing Information. Merck & Co. Inc.; 2025. 3. Opdivo. Prescribing Information. Bristol-Myers Squibb Company; 2025.